Hypoglycemic drugs

CAT # Product Name Description
CPDA0004 Ertugliflozin Ertugliflozin, also known as also known as PF-04971729, is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
CPDA0048 Omarigliptin Omarigliptin, also known as MK-3102, is a potent and long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
CPDA1089 Retagliptin Retagliptin, also known as SP-2086, is a DPP-4 inhibitor potentially used for the treatment of Type 2 diabetes.
CPDA0088 Trelagliptin Trelagliptin, also known as SYR-472, is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D).
CPDA2039 Linagliptin Linagliptin, also known as BI-1356, is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.
CPDA0100 Sitagliptin Sitagliptin (INN; previously identified as MK-0431 and sold under the trade name Januvia) is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
CPD0854 LX-4211 LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.
CPDA1553 LX-2761 LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.
CPDA0045 Ipragliflozin Ipragliflozin, also known as ASP1941, is a potent and selective SGLT2 inhibitor for treatment of type 2 diabetes.


Contact Us

Inquiry

Latest News

  • Top 7 Trends In Pharmaceutical Research In 2018

    Top 7 Trends In Pharmaceutical Research I...

      Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

  • ARS-1620: A promising new inhibitor for KRAS-mutant cancers

    ARS-1620: A promising new inhibitor for K...

    According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

  • AstraZeneca receives regulatory boost for oncology drugs

    AstraZeneca receives regulatory boost for...

    AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

WhatsApp Online Chat !